O	0	6	Effect
O	7	9	of
B-intervention	10	17	aerobic
I-intervention	18	26	exercise
I-intervention	27	39	intervention
O	40	42	on
O	43	50	markers
O	51	53	of
O	54	61	insulin
O	62	72	resistance
O	73	75	in
O	76	82	breast
O	83	89	cancer
O	90	95	women
O	95	96	.

O	97	104	Insulin
O	105	108	may
O	109	115	affect
O	116	122	breast
O	123	129	cancer
O	130	131	(
O	131	133	BC
O	133	134	)
O	135	139	risk
O	140	143	and
O	144	153	prognosis
O	153	154	.

O	155	163	Exercise
O	164	171	reduces
O	172	179	insulin
O	180	182	in
O	183	188	obese
O	189	191	BC
O	192	201	survivors
O	201	202	.

O	203	205	We
O	206	214	designed
O	215	216	a
O	217	227	randomised
O	228	238	controlled
O	239	244	trial
O	245	247	to
O	248	252	test
O	253	256	the
O	257	263	effect
O	264	266	of
O	267	269	an
O	270	277	aerobic
O	278	286	exercise
O	287	299	intervention
O	300	301	(
O	301	304	AEI
O	304	305	)
O	306	308	on
O	309	316	insulin
O	317	327	parameters
O	328	331	and
O	332	336	body
O	337	348	composition
O	349	351	in
B-eligibility	352	355	non
I-eligibility	355	356	-
I-eligibility	356	361	obese
I-eligibility	362	364	BC
I-eligibility	365	370	women
I-eligibility	371	378	without
I-eligibility	379	386	insulin
I-eligibility	387	397	resistance
O	397	398	.

B-total-participants	399	405	Thirty
I-total-participants	405	406	-
I-total-participants	406	411	eight
O	412	414	BC
O	415	420	women
O	421	425	were
O	426	436	randomised
O	437	441	into
O	442	444	an
O	445	457	intervention
O	458	463	group
O	464	465	(
O	465	467	IG
O	468	469	=
B-intervention-participants	470	472	18
O	472	473	)
O	474	476	or
B-control	477	484	control
I-control	485	490	group
O	491	492	(
O	492	494	CG
O	495	496	=
B-control-participants	497	499	20
O	499	500	)
O	500	501	.

O	502	504	IG
O	505	517	participated
O	518	520	in
O	521	522	a
O	523	533	structured
O	534	537	AEI
O	538	541	for
O	542	543	3
O	544	550	months
O	550	551	,
O	552	557	while
O	558	560	CG
O	561	569	received
O	570	574	only
O	575	578	the
O	579	583	Word
O	584	590	Cancer
O	591	599	Research
O	600	604	Fund
O	604	605	/
O	605	613	American
O	614	623	Institute
O	624	630	Cancer
O	631	639	Research
O	640	641	(
O	641	645	WCRF
O	645	646	/
O	646	650	AICR
O	650	651	)
O	652	666	recommendation
O	667	669	to
O	670	672	be
O	673	683	physically
O	684	690	active
O	690	691	.

O	692	699	Fasting
O	700	707	insulin
O	707	708	,
O	709	720	homeostasis
O	721	726	model
O	727	737	assessment
O	738	740	of
O	741	748	insulin
O	749	759	resistance
O	760	761	(
O	761	765	HOMA
O	765	766	-
O	766	768	IR
O	768	769	)
O	770	775	index
O	775	776	,
O	777	786	metabolic
O	787	797	parameters
O	798	801	and
O	802	806	body
O	807	818	composition
O	819	823	were
O	824	833	collected
O	834	836	at
O	837	845	baseline
O	846	849	and
O	850	855	after
O	856	859	the
O	860	863	AEI
O	863	864	.

O	865	867	IG
O	868	875	reduced
B-outcome	876	883	insulin
I-outcome	884	887	and
I-outcome	888	892	HOMA
I-outcome	892	893	-
I-outcome	893	895	IR
I-outcome	896	901	index
O	902	904	by
O	905	907	15
O	907	908	%
O	909	912	and
O	913	915	14
O	915	916	%
O	916	917	,
O	918	923	while
O	924	926	CG
O	927	936	increased
O	937	942	these
O	943	953	parameters
O	954	955	(
O	955	956	+
O	956	958	12
O	958	959	%
O	960	963	and
O	964	965	+
O	965	967	16
O	967	968	%
O	968	969	)
O	969	970	.

O	971	978	Insulin
O	979	986	changed
O	987	998	differently
O	999	1003	over
O	1004	1008	time
O	1009	1011	in
O	1012	1015	the
O	1016	1019	two
O	1020	1030	randomised
O	1031	1037	groups
O	1038	1039	(
O	1039	1051	pinteraction
O	1053	1054	=
O	1055	1056	.
O	1056	1058	04
O	1058	1059	)
O	1059	1060	.

O	1061	1064	The
O	1065	1072	between
O	1072	1073	-
O	1073	1078	group
O	1079	1090	differences
O	1091	1093	in
O	1094	1097	the
B-outcome	1098	1104	change
I-outcome	1105	1107	of
I-outcome	1108	1115	insulin
O	1116	1117	(
O	1117	1119	IG
O	1120	1121	=
O	1122	1123	-
O	1123	1124	1
O	1124	1125	.
O	1125	1126	2
O	1127	1128	μ
O	1128	1129	U
O	1129	1130	/
O	1130	1132	ml
O	1133	1139	versus
O	1140	1142	CG
O	1143	1144	=
O	1145	1146	+
O	1146	1147	0
O	1147	1148	.
O	1148	1149	8
O	1150	1151	μ
O	1151	1152	U
O	1152	1153	/
O	1153	1155	ml
O	1155	1156	)
O	1157	1160	and
B-outcome	1161	1165	HOMA
I-outcome	1165	1166	-
I-outcome	1166	1168	IR
I-outcome	1169	1174	index
O	1175	1176	(
O	1176	1178	IG
O	1179	1180	=
O	1181	1182	-
O	1182	1183	0
O	1183	1184	.
O	1184	1186	26
O	1187	1193	versus
O	1194	1196	CG
O	1197	1198	=
O	1199	1200	+
O	1200	1201	0
O	1201	1202	.
O	1202	1204	25
O	1204	1205	)
O	1206	1210	were
O	1211	1223	respectively
O	1224	1235	significant
O	1236	1237	(
O	1237	1238	p
O	1239	1240	=
O	1241	1242	.
O	1242	1244	04
O	1244	1245	)
O	1246	1249	and
O	1250	1253	non
O	1253	1254	-
O	1254	1265	significant
O	1266	1267	(
O	1267	1268	p
O	1269	1270	=
O	1271	1272	.
O	1272	1274	06
O	1274	1275	)
O	1275	1276	.

O	1277	1279	IG
O	1280	1293	significantly
O	1294	1302	improved
B-outcome	1303	1308	lower
I-outcome	1309	1313	limb
I-outcome	1314	1320	muscle
I-outcome	1321	1325	mass
O	1326	1328	in
O	1329	1339	comparison
O	1340	1344	with
O	1345	1347	CG
O	1348	1349	(
O	1349	1350	p
O	1351	1352	=
O	1353	1354	.
O	1354	1356	03
O	1356	1357	)
O	1357	1358	.

O	1359	1360	A
O	1361	1371	structured
O	1372	1375	AEI
O	1376	1379	may
O	1380	1387	improve
O	1388	1395	insulin
O	1395	1396	,
O	1397	1401	HOMA
O	1401	1402	-
O	1402	1404	IR
O	1405	1410	index
O	1411	1414	and
O	1415	1419	body
O	1420	1431	composition
O	1432	1434	in
O	1435	1438	non
O	1438	1439	-
O	1439	1444	obese
O	1445	1447	BC
O	1448	1457	survivors
O	1458	1465	without
O	1466	1473	insulin
O	1474	1484	resistance
O	1484	1485	.
